A retrospective evaluation of the presentation, prognostic factors and outcomes of neuroblastoma in Ugandan children

References

• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–216. doi:10.1038/nrc1014. PMID: 12612655.
   PubMed Web of Science ®Google Scholar
• David R, Lamki N, Fan S, et al. The many faces of neuroblastoma. Radiographics. 1989;9(5):859–882. doi:10.1148/radiographics.9.5.2678295. PMID: 2678295.
   PubMedGoogle Scholar
• Solovyov A, Morgun V, Paholchuk A. Neuroblastoma in pediatric patients. Klin Khir. 2015;6(6):59–61. Russian. PMID: 26521471.
   Google Scholar
• Miller RW, L Young J, Jr, Novakovic B. Childhood cancer. Cancer. 1995;75(S1):395–405. PMID: 7534639. doi:10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W.
   PubMedGoogle Scholar
• Van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. World J Clin Oncol. 2020;11(8):629–643. doi:10.5306/wjco.v11.i8.629. PMID: 32879849; PMCID: PMC7443833.
   PubMed Web of Science ®Google Scholar
• Parikh NS, Howard SC, Chantada G, International Society of Pediatric Oncology, et al. SIOP‐PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low‐and middle‐income settings. Pediatr Blood Cancer. 2015;62(8):1305–1316. doi:10.1002/pbc.25501. Epub 2015 Mar 21. PMID: 25810263; PMCID: PMC5132052.
   PubMed Web of Science ®Google Scholar
• Herd F, Basta NO, McNally RJ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. 2019;111(4):50–58. doi:10.1016/j.ejca.2018.12.032. Epub 2019 Feb 26. PMID: 30822684; PMCID: PMC6458963.
   PubMedGoogle Scholar
• Mora J, Gerald WL, Cheung N-KV. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett. 2003;197(1-2):119–124. PMID: 12880970. doi:10.1016/S0304-3835(03)00094-6.
   PubMed Web of Science ®Google Scholar
• Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018;5(9):114. PMID: 30154341; PMCID: PMC6162495. doi:10.3390/children5090114.
   PubMedGoogle Scholar
• Sharma R, Mer J, Lion A, Vik TA. Clinical presentation, evaluation, and management of neuroblastoma. Pediatr Rev. 2018;39(4):194–203. doi:10.1542/pir.2017-0087. PMID: 29610427.
   PubMed Web of Science ®Google Scholar
• Autier P, Sullivan R. Population screening for cancer in high-income settings: Lessons for low-and middle-income economies. J Glob Oncol. 2019;5(2):1–5. doi:10.1200/JGO.18.00235. PMID: 30715958; PMCID: PMC6426516.
   PubMedGoogle Scholar
• Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. The Lancet. 1996;348(9043):1682–1687. PMID: 8973429. doi:10.1016/S0140-6736(96)06020-5.
   PubMed Web of Science ®Google Scholar
• Esteve J, Parker L, Roy P, et al. Is neuroblastoma screening evaluation needed and feasible? Br J Cancer. 1995;71(6):1125–1131. PMID: 7779698; PMCID: PMC2033839. doi:10.1038/bjc.1995.219.
   PubMed Web of Science ®Google Scholar
• Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350(19):2010–2011. doi:10.1056/NEJM200405063501922. PMID: 15128908.
   PubMed Web of Science ®Google Scholar
• Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2017;35(22):2580–2587. doi:10.1200/JCO.2016.72.0177. Epub 2017 May 4. PMID: 28471719; PMCID: PMC5676955.
   PubMed Web of Science ®Google Scholar
• Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South Africa between 2000 and 2014. Pediatr Blood Cancer. 2019;66(11):e27944. doi:10.1002/pbc.27944. Epub 2019 Jul 31. PMID: 31368239.
   PubMed Web of Science ®Google Scholar
• Aydn GB, Kutluk MT, Yalçn B, et al. Neuroblastoma in Turkish children: experience of a single center. J Pediatr Hematol Oncol. 2009;31(7):471–480. doi:10.1097/MPH.0b013e3181a6dea4. PMID: 19564739.
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, London WB, Stephens D, et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016;65:1–10. doi:10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17. PMID: 27434878.
   PubMed Web of Science ®Google Scholar
• Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi: 10.1016/j.pcl.2007.10.014. PMID: 18242317.
   PubMed Web of Science ®Google Scholar
• Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45(7):1172–1188. PMID: 15235064.
   PubMed Web of Science ®Google Scholar
• Al‑Tonbary Y, Badr M, Mansour A, et al. Clinico-epidemiology of neuroblastoma in north east Egypt: a 5-year multicenter study. Oncology Letters. 2015;10(2):1054–1062. Epub 2015 Jun 8. PMID: 26622625; PMCID: PMC4509073. doi:10.3892/ol.2015.3335.
   PubMed Web of Science ®Google Scholar
• Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–3017. doi:10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. PMID: 26304901; PMCID: PMC4567703.
   PubMed Web of Science ®Google Scholar
• Hesseling P, Ankone K, Wessels G, Schneider J, Du Plessis L, Moore S. Neuroblastoma in southern Africa: Epidemiological features, prognostic factors and outcome. Ann Trop Paediatr. 1999;19(4):357–363. doi:10.1080/02724939992202. PMID: 10716030.
   PubMed Web of Science ®Google Scholar
• Kitonyi G, Macharia W, Mwanda OW, Pamnani R. Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the Kenyatta National Hospital, Nairobi. E Af Med Jrnl. 2010;86(12):39–45. PMID: 21591508. doi:10.4314/eamj.v86i12.62899.
   Google Scholar
• George PE, Fahdil G, Luutu I, et al. Analysis of management decisions and outcomes of a weekly multidisciplinary pediatric tumor board meeting in Uganda. Future Sci OA. 2019;5(9):FSO417. doi:10.2144/fsoa-2019-0070. PMID: 31608156; PMCID: PMC6787502.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Poetschger U, Valteau-Couanet D, et al. Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1. 5 International Society of Pediatric Oncology European Neuroblastoma Group study. J Clin Oncol. 2021;39(23):2552–2563. doi:10.1200/JCO.20.03144. Epub 2021 Jun 21. PMID: 34152804.
   PubMed Web of Science ®Google Scholar
• Georgakis MK, Dessypris N, Baka M, et al. Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in incidence and temporal trends compared to US. Int J Cancer. 2018;142(10):1977–1985. doi:10.1002/ijc.31222. Epub 2017 Dec 29. PMID: 29250786.
   PubMed Web of Science ®Google Scholar
• Tas ML, Nagtegaal M, Kraal KC, et al. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatr Blood Cancer. 2020;67(4):e28061. doi:10.1002/pbc.28061. Epub 2019 Nov 17. PMID: 31736229.
   PubMed Web of Science ®Google Scholar
• Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol. 2012;30(15):1842–1848. doi:10.1200/JCO.2011.37.9990. Epub 2012 Apr 23. PMID: 22529259; PMCID: PMC3383182.
   PubMed Web of Science ®Google Scholar
• DuBois SG, London WB, Zhang Y, et al. Lung metastases in neuroblastoma at initial diagnosis: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008;51(5):589–592. doi:10.1002/pbc.21684. PMID: 18649370; PMCID: PMC2746936.
   PubMed Web of Science ®Google Scholar
• Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–220. doi:10.1016/j.it.2016.01.004. Epub 2016 Feb 6. PMID: 26858199; PMCID: PMC4775398.
   PubMed Web of Science ®Google Scholar
• Frosch J, Leontari I, Anderson J. Combined effects of myeloid cells in the neuroblastoma tumor microenvironment. Cancers. 2021;13(7):1743. PMID: 33917501; PMCID: PMC8038814. doi:10.3390/cancers13071743.
   PubMed Web of Science ®Google Scholar
• Webb MW, Sun J, Sheard MA, et al. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer. 2018;143(6):1483–1493. doi:10.1002/ijc.31532. Epub 2018 May 7. PMID: 29665011; PMCID: PMC6105468.
   PubMed Web of Science ®Google Scholar